[
    {
        "category": "company",
        "datetime": 1743522637,
        "headline": "Biotech stocks slide as Marks resignation seen being negative for sector",
        "id": 133645467,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration\u2019s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is \u201cnot good for the biotech industry even beyond vaccines.\u201d Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a \u201csignificant negative\u201d for the biopharma and biotech sectors. \u201cNOT GOOD\u201d FOR BIOTECH SECTOR: RBC Capit",
        "url": "https://finnhub.io/api/news?id=254d158cbf2c958ffa39dd784453958618f4931103736807bbadab76abc44dcf"
    },
    {
        "category": "company",
        "datetime": 1743522007,
        "headline": "GILD or AMGN: Which Is the Better Value Stock Right Now?",
        "id": 133655234,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "GILD vs. AMGN: Which Stock Is the Better Value Option?",
        "url": "https://finnhub.io/api/news?id=4a606a31dbc49f767cf9afc7f05806d74555d9134bd2e4120d87627ed51612d3"
    },
    {
        "category": "company",
        "datetime": 1743512100,
        "headline": "Discovering a Breakthrough: Gilead\u2019s Long-Standing Commitment to Helping Change the Course of HIV",
        "id": 133645419,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "NORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years ...",
        "url": "https://finnhub.io/api/news?id=a4a4595109d42c1c0bde63836635ad06185f62e912184556c4c3139a8e126882"
    },
    {
        "category": "company",
        "datetime": 1743507120,
        "headline": "Impax U.S. Sustainable Economy Fund Q4 2024 Commentary",
        "id": 133644643,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1481194928/image_1481194928.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "During the fourth quarter of 2024, the US International Sustainable Economy portfolio underperformed the Russell 1000 benchmark. Read more here.",
        "url": "https://finnhub.io/api/news?id=99d9b8efe5edf830404917aa0e1ce4cd2992cf5577f50da15928e27fd6c873e4"
    },
    {
        "category": "company",
        "datetime": 1743507025,
        "headline": "These biotech names aren't facing 'huge concern' from tariffs",
        "id": 133645380,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with overseas production. Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizing Vertex (VRTX), Amgen (AMGN), and Gilead (GILD) as some of his top large-cap picks in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime\u00a0here.",
        "url": "https://finnhub.io/api/news?id=3c95152d520015603efbbfe60d018817dd7753417c24b8ffe43796a8e6ed66ce"
    },
    {
        "category": "company",
        "datetime": 1743498612,
        "headline": "Discovering a Breakthrough: Gilead's Long-Standing Commitment to Helping Change the Course of HIV",
        "id": 133635173,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years...",
        "url": "https://finnhub.io/api/news?id=888bbbfbeee98738840f3691d7f3d7ff2555d9e0e3a7ffe0232785ad4049da7d"
    },
    {
        "category": "company",
        "datetime": 1743491721,
        "headline": "Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company",
        "id": 133634442,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2164256928/image_2164256928.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider investing in CORT stock.",
        "url": "https://finnhub.io/api/news?id=6d3999a58f1fa9a321b0c9d56bd51dbd5f295b378e3787266cd5533d0cd47cfc"
    },
    {
        "category": "company",
        "datetime": 1743429442,
        "headline": "Moderna, biotech stocks slide following resignation of FDA official Peter Marks",
        "id": 133627876,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.",
        "url": "https://finnhub.io/api/news?id=13807fe3b03fa7efe54dc0183e175ee669f38d55b3e26bfaa8c99d100a90cfbc"
    },
    {
        "category": "company",
        "datetime": 1743426113,
        "headline": "1 Healthcare Stock to Target This Week and 2 to Turn Down",
        "id": 133627791,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry\u2019s returns - over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500\u2019s 4% decline.",
        "url": "https://finnhub.io/api/news?id=70cf00c471c5a3487d6fe002761b6cc0869dd2cd1109a7ecd7768740deb86de0"
    },
    {
        "category": "company",
        "datetime": 1743418020,
        "headline": "Moderna Stock Sinks After Top FDA Official Resigns; Sarepta Gets Hit, Too.",
        "id": 134149025,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Moderna Stock Sinks After Top FDA Official Resigns; Sarepta Gets Hit, Too.",
        "url": "https://finnhub.io/api/news?id=6f5ad47d886d049ff7c08c551452e552c25e1821debf4c78b6b5b31b9f2b050f"
    },
    {
        "category": "company",
        "datetime": 1743412620,
        "headline": "Hartford Quality Value ETF Q4 2024 Commentary",
        "id": 133626227,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1364946137/image_1364946137.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Hartford Quality Value ETF underperformed the Russell 1000 Value Index during the quarter. Read more here.",
        "url": "https://finnhub.io/api/news?id=d4936e7df23d7556069752f60450e0e5a2cab4c0e9253a3bf859fa6313683bda"
    },
    {
        "category": "company",
        "datetime": 1743321600,
        "headline": "Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)",
        "id": 133610520,
        "image": "",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=5396dc50bae2cf88fb2cad0e40ff1bb7979c1a7a66573670cb244f4dcfa85011"
    },
    {
        "category": "company",
        "datetime": 1743310800,
        "headline": "Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors",
        "id": 133598030,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453972690/image_1453972690.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.",
        "url": "https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87"
    },
    {
        "category": "company",
        "datetime": 1743306600,
        "headline": "abrdn Life Sciences Investors Q4 2024 Commentary",
        "id": 133594341,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205513/image_1322205513.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "The equity portion of the Abrdn Life Sciences Investors Fund fell (gross) but outperformed its benchmark for Q4 2024. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=66dc9f2b53ce613484d516524a22eafdccbe115cabd59877c7d52f9cd1ad811b"
    },
    {
        "category": "company",
        "datetime": 1743303000,
        "headline": "abrdn Healthcare Investors Q4 2024 Commentary",
        "id": 133590926,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91598774/image_91598774.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=82f91dbf63848ebe808f64808c8e5edf8521e08d31f59b25f79fc61ada48f984"
    },
    {
        "category": "company",
        "datetime": 1743182630,
        "headline": "Gilead Sciences (NasdaqGS:GILD) Faces Shareholder Proposals As Stock Rises 5%",
        "id": 133523855,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the separation of the Chairman and CEO roles and developing a comprehensive human rights policy. The company advised voting against these proposals, slated for discussion at the upcoming annual meeting. Despite broader market challenges like the Dow's 1.7% decline and inflation concerns, Gilead's stock rose 18% over the last quarter, potentially buoyed by its robust Q4...",
        "url": "https://finnhub.io/api/news?id=d2ec35ff87d25c53aeea261704899a65debaa5e170936332a3f854f1f16d2994"
    },
    {
        "category": "company",
        "datetime": 1743093460,
        "headline": "Gilead Says CEO Daniel O'Day's 2024 Total Compensation Was $23.7 Million - SEC Filing",
        "id": 133485504,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "Gilead Sciences Inc: * GILEAD SAYS CEO DANIEL O\u2019DAY'S 2024 TOTAL COMPENSATION WAS$23.7MILLION - SEC FILING * GILEAD - BOARD RECOMMENDS TO VOTE AGAINST...",
        "url": "https://finnhub.io/api/news?id=c1b13bc0ffbd7d9c27a7931fe77f6fab7fd2c330885973036ac9d7bb27cc06c9"
    },
    {
        "category": "company",
        "datetime": 1743073681,
        "headline": "High Growth Tech Stocks in the US Market",
        "id": 133468153,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "The United States market has remained flat over the past week but has shown an 8.5% increase over the past year, with earnings expected to grow by 14% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in capturing emerging opportunities within this dynamic sector.",
        "url": "https://finnhub.io/api/news?id=4403f6275052201ec483613e297563eae552c6553df888f8c8470a9d58d6bf32"
    },
    {
        "category": "company",
        "datetime": 1743070920,
        "headline": "Trump Weighs Tariffs on Pharma in Ireland. What It Means for Amgen, Gilead.",
        "id": 134148459,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Trump Weighs Tariffs on Pharma in Ireland. What It Means for Amgen, Gilead.",
        "url": "https://finnhub.io/api/news?id=963858e4e1f3ef91c07929e71bcdd8933db7df8363b7703b9afa50320998706c"
    },
    {
        "category": "company",
        "datetime": 1743060600,
        "headline": "Franklin Biotechnology Discovery Fund Q4 2024 Commentary",
        "id": 133467152,
        "image": "",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=743b5137aca60badcb2ace1e5601b3a1d46e916bce67c484c60523c28bfb157b"
    },
    {
        "category": "company",
        "datetime": 1743007500,
        "headline": "Gilead\u2019s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise.",
        "id": 133462147,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences  stock has room to climb, and investors shouldn\u2019t overlook the company\u2019s impressive record in navigating HIV policy, Citi Research says.  Analysts led by Geoff Meacham reiterated a Buy rating on the shares with a $125 price target in a note Wednesday.  With Gilead up 1.2% to $109.23 on Wednesday, the price target suggests potential upside of 14%.",
        "url": "https://finnhub.io/api/news?id=0f6c0b0e195b590471da04344a4333cd95dda6e4e7ec441563448a84b79492c5"
    },
    {
        "category": "company",
        "datetime": 1742996411,
        "headline": "Are Medical Stocks Lagging  Gilead Sciences (GILD) This Year?",
        "id": 133457273,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Here is how Gilead Sciences (GILD) and AngioDynamics (ANGO) have performed compared to their sector so far this year.",
        "url": "https://finnhub.io/api/news?id=b3f241b6a1e0fc549cb13d8b5b36c7ba0273f79e9a255d089d5a51fe14485133"
    },
    {
        "category": "company",
        "datetime": 1742920620,
        "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
        "id": 133452256,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
        "url": "https://finnhub.io/api/news?id=c8d4d884b6aeccf34d2076d8ff6cee8c2e3fa6394318d7fe3f4fbfa0ea315375"
    },
    {
        "category": "company",
        "datetime": 1742909100,
        "headline": "Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer",
        "id": 133375707,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "NORTHAMPTON, MA / ACCESS Newswire / March 25, 2025 / HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can negatively impact patients and their treatment. Now lessons learned from the ...",
        "url": "https://finnhub.io/api/news?id=e20e2c21094ada259085cec0214d6a5a94f198efd37b50d7515e7452401be594"
    },
    {
        "category": "company",
        "datetime": 1742853015,
        "headline": "Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note",
        "id": 133360449,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.",
        "url": "https://finnhub.io/api/news?id=e3e463a424a79ecddfa8a29832c364beae18f7b84919089ca7b9ee94b2b735c4"
    },
    {
        "category": "company",
        "datetime": 1742733367,
        "headline": "Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval",
        "id": 133330583,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2205820023/image_2205820023.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential for 2024.",
        "url": "https://finnhub.io/api/news?id=5cfa6a663c0d174404a041d52d80f01a99c0befe5d6ffa3ebf56b6050c965f60"
    },
    {
        "category": "company",
        "datetime": 1742603490,
        "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of March 23",
        "id": 133312311,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1455774438/image_1455774438.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Stay updated with weekly dividend activity for Champions, Contenders, and Challengers. Learn about changes, ex-dividend dates, and upcoming pay dates.",
        "url": "https://finnhub.io/api/news?id=a00a20610d7c0e7c3f3efd7fa8ee5ab49b5686743cf4228ce0455695ca1bb661"
    },
    {
        "category": "company",
        "datetime": 1742566575,
        "headline": "Trump Trade: President to sign EO on DOE, weighing Chevron license extension",
        "id": 133324235,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: DEPARTMENT OF EDUCATION: President Donald Trump is expected to sign an executive order Thursday to close the Education Department, fulfilling a yearslong pledge to dismantle the federal agency, the White House confirmed, report Garrett Haake, Nnamdi Egwuonwu and Tyler Kingkade of NBC News. Trump",
        "url": "https://finnhub.io/api/news?id=e8c94c43e7f12c68a0723f0935e4cbe0113347992318662e437240856853583b"
    },
    {
        "category": "company",
        "datetime": 1742547929,
        "headline": "Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)",
        "id": 133325382,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "As the Q4 earnings season comes to a close, it\u2019s time to take stock of this quarter\u2019s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.",
        "url": "https://finnhub.io/api/news?id=d707e8f3b0cc0fa822c090325019c202720f707ddbcc4a275332705e626f8505"
    },
    {
        "category": "company",
        "datetime": 1742546760,
        "headline": "The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics",
        "id": 133325383,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.",
        "url": "https://finnhub.io/api/news?id=04a20663c3b5c3252152e08965c8349fa1d9aca071098d6ace3567837727d3e0"
    },
    {
        "category": "company",
        "datetime": 1742524200,
        "headline": "Incyte Had a Bad Week. Investors Are Used to It.",
        "id": 134149028,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Incyte Had a Bad Week. Investors Are Used to It.",
        "url": "https://finnhub.io/api/news?id=eed75c0438f0083066a4e4de9cfe7de33bb9579b0699b9c9c7216de553746825"
    },
    {
        "category": "company",
        "datetime": 1742508018,
        "headline": "Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights",
        "id": 133325384,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the preceding trading day.",
        "url": "https://finnhub.io/api/news?id=367e15ce3fac067b6215bf0bc1af9dff4b91555ac527258de0bb182ab60b34bd"
    },
    {
        "category": "company",
        "datetime": 1742497200,
        "headline": "GILD Stock Down on Report of Cut in HIV Prevention Spending",
        "id": 133325385,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash funding for HIV prevention in the country.",
        "url": "https://finnhub.io/api/news?id=be9bdf9cb05116790be45848c159ff14b1bd6f2a82757ca20ef1ca5eb0a02b5b"
    },
    {
        "category": "company",
        "datetime": 1742482849,
        "headline": "Oppenheimer doesn\u2019t see threat to Gilead estimates after HHS plans for HIV cuts",
        "id": 133325386,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services department is mulling cuts to federal HIV prevention funding, though \u201cit sounds like\u201d the cuts would only impact funding for statewide prevention initiatives and not reimbursement for preventative treatments like lenacapavir. Given the uncertainties surrounding this administration, he news \u201cbegs the question: What if?\u201d Right now, pre-exposure prophylaxis, or",
        "url": "https://finnhub.io/api/news?id=751bf876d7c1f6d7b09b36bd6c4771df3768a661c67098f2ddccdb5aa89fdd79"
    },
    {
        "category": "company",
        "datetime": 1742479258,
        "headline": "Trump Trade: Reciprocal tariffs still to start on April 2",
        "id": 133323810,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: RECIPROCAL TARIFFS: President Donald Trump intends for new reciprocal tariff rates to start on April 2, Andrea Shalal and David Lawder of Reuters report. \u201cThe intent is to enact tariffs on April 2,\u201d a white house official said, according to the publication. \u201cUnless the tariff and non-tariff barri",
        "url": "https://finnhub.io/api/news?id=1fb98fafa6e26a50cb813074f816f6d46993b58c90b1e0832c973e130c8fda5b"
    },
    {
        "category": "company",
        "datetime": 1742477410,
        "headline": "Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet",
        "id": 133325388,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
        "url": "https://finnhub.io/api/news?id=975ee1dfa9a06d6e797dd9e7bba3de74edea53a7dc8638a148cf721d5cc1a743"
    },
    {
        "category": "company",
        "datetime": 1742469633,
        "headline": "Defensive Stocks For Unpredictable Trump Policy",
        "id": 133281246,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2185636755/image_2185636755.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Navigate market volatility with defensive stocks, bonds, and gold.",
        "url": "https://finnhub.io/api/news?id=3a7f34c516b912e4da5e6ab19d098a97e373f71f94dfa6f751a599d77a1b754c"
    },
    {
        "category": "company",
        "datetime": 1742463648,
        "headline": "My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 11 Buys",
        "id": 133276011,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "February investments fell below $1,000, mainly in BDCs like Owl Rock Capital and Ares Capital, boosting annual dividend income by $77.",
        "url": "https://finnhub.io/api/news?id=468f86fd4b412eee1971a4620667bbda7347c15c7444f076c7a1ef8f0edb1137"
    },
    {
        "category": "company",
        "datetime": 1742461500,
        "headline": "Invesco Health Care Fund Q4 2024 Commentary",
        "id": 133273550,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.",
        "url": "https://finnhub.io/api/news?id=8f81827abb6ec00be306ef52a83e31acbe2c243bf3d6f7d992305822a81d2a8e"
    },
    {
        "category": "company",
        "datetime": 1742438174,
        "headline": "Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides",
        "id": 133325389,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences Inc (NASDAQ:GILD) stock is trading lower during the premarket trading session on Wednesday. According to a Tuesday report in the Wall Street Journal, the Health and Human Services Department (HHS) is considering substantial reductions ...",
        "url": "https://finnhub.io/api/news?id=ee2c883b66d1868e5eddeb93929f596eabdce758da104964c5a6d71c60cf97dc"
    },
    {
        "category": "company",
        "datetime": 1742419384,
        "headline": "Gilead stock falls on report of HIV prevention cuts",
        "id": 133325390,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Shares of Gilead Sciences (GILD) fell 2% on Wednesday following a Wall Street Journal report that the Trump administration is considering making cuts to domestic HIV prevention efforts. Yahoo Finance Health Reporter Anjalee Khemlani discusses the latest in the video above. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
        "url": "https://finnhub.io/api/news?id=9db08c0e5a57852932e2d6feac016a18c67d0ad86358a71d2eeb69ea93af8ef1"
    },
    {
        "category": "company",
        "datetime": 1742417220,
        "headline": "These Stocks Moved the Most Today: Nvidia, Tesla, Boeing, Autodesk, Gilead, Signet, Williams-Sonoma, and More",
        "id": 133325391,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Nvidia stock rises after the chip maker makes a number of product announcements at its annual AI GTC conference, Tesla trades higher after sharp slumps earlier this week, and Boeing\u2019s chief financial officer says the company doesn\u2019t see a material near-term impact from tariffs on its supply chain.",
        "url": "https://finnhub.io/api/news?id=52dafb64ff180a7e5bb046311960ce0ec5c0481b0452ee25e005f1ee2e5950b0"
    },
    {
        "category": "company",
        "datetime": 1742414525,
        "headline": "Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding",
        "id": 133325392,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' topline.",
        "url": "https://finnhub.io/api/news?id=b8e93c58fd60539827ab4cc3e92131c693bdab64181a2b0bef867820e29f3e85"
    },
    {
        "category": "company",
        "datetime": 1742409153,
        "headline": "Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts",
        "id": 133325393,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Investing.com -- Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human Services Department is considering major cuts to federal funding for domestic HIV prevention programs.",
        "url": "https://finnhub.io/api/news?id=20db17cbd76d25f8f828e5eb250ce2ee9b343a19ad42c09b4ed4a098f9339a41"
    },
    {
        "category": "company",
        "datetime": 1742399117,
        "headline": "Stocks to Watch Wednesday: Nvidia, Shopify, Williams-Sonoma, Tesla",
        "id": 133325394,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "\u2198\ufe0f Gilead Sciences (GILD): The Trump administration is weighing plans to slash funding for HIV prevention; such cuts could affect drugmakers Gilead and Viiv Healthcare. Gilead stock fell Wednesday afternoon, as did shares in GSK (GSK), the majority owner of ViiV.",
        "url": "https://finnhub.io/api/news?id=ccd80427d35d885f6236b42b59c4624d55fef1cc40b5298c599c3d42a0f953c7"
    },
    {
        "category": "company",
        "datetime": 1742397630,
        "headline": "Gilead Sciences Should Not See Any Impact From HIV-Related Cost Reductions at US Healthcare Department, Truist Says",
        "id": 133325395,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences (GILD) should not see any impact from the reported cost reductions at the US Departm",
        "url": "https://finnhub.io/api/news?id=c2f1d2d3ee584644f7d343737aa6958e62d32c52198950a0317fa4c0bfc5714a"
    },
    {
        "category": "company",
        "datetime": 1742397180,
        "headline": "FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review",
        "id": 133325059,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.",
        "url": "https://finnhub.io/api/news?id=680e92563ff55e9cf92e684f269a9a0f0ecfe386216b43ca15b520979fde53b7"
    },
    {
        "category": "company",
        "datetime": 1742395802,
        "headline": "HIV Drug Makers Get Spooked by Possible Trump Cut, but Impact Looks Manageable",
        "id": 133325397,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%.  Shares of both Gilead and GSK, another HIV-focused drugmaker, fell after The Wall Street Journal reported the administration was considering drastic cuts to funding for domestic HIV prevention.  Perhaps more important is that the potential cuts come as investors are increasingly worried about broader potential reductions to Medicaid, which could impact access to HIV drugs.",
        "url": "https://finnhub.io/api/news?id=3c500758261e3840bb7eedbc6170ea97c0e4494b22588a6e153164d5ef9b5514"
    },
    {
        "category": "company",
        "datetime": 1742394732,
        "headline": "Why Gilead Sciences (GILD) Is Among the Most Undervalued Biotech Stocks to Invest In",
        "id": 133325398,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other most undervalued biotech stocks to invest in. Trump\u2019s Tariffs and the Pharma Sector On February 21, Jared Holz, Mizuho Securities [\u2026]",
        "url": "https://finnhub.io/api/news?id=7189a8614ea27802142d62c7be933d9c01916411c0ba9f3d5c955ff30c386dd1"
    },
    {
        "category": "company",
        "datetime": 1742393220,
        "headline": "Buy 3 U.S. Giants Flying High Year to Date Defying Severe Volatility",
        "id": 133321655,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Three U.S. bigwigs flying high year to date with more upside are GILD, GE and PGR.",
        "url": "https://finnhub.io/api/news?id=4823552375ad14ba3b6d9bb7a56f6bca53185eac3866dc58365fa9f0e57901a0"
    },
    {
        "category": "company",
        "datetime": 1742392800,
        "headline": "Gilead Stock Falls on Report Trump Administration Wants to Cut\u00a0HIV-Prevention Funding",
        "id": 133325400,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences  stock declined Wednesday after The Wall Street Journal reported the Department of Health and Human Services was considering federal funding cuts to domestic HIV prevention.  The Centers for Disease Control and Prevention, an arm of the HHS, has a Division of HIV Prevention dating back to the 1980s.  In addition to tracking HIV infections across the country, it focuses on community outreach, working with state and local leaders to promote testing and prevention.",
        "url": "https://finnhub.io/api/news?id=1a910fd9b3958e35d079791d02374f968e69da2219215536abca834aa309f617"
    },
    {
        "category": "company",
        "datetime": 1742387340,
        "headline": "Health Care Roundup: Market Talk",
        "id": 133267051,
        "image": "",
        "related": "GILD",
        "source": "DowJones",
        "summary": "Health Care Roundup: Market Talk",
        "url": "https://finnhub.io/api/news?id=dcdf6a2e893a55de2f10dc41ca63cf518f91ab21712c8d5481f7205d264c3d6f"
    },
    {
        "category": "company",
        "datetime": 1742369160,
        "headline": "These Stocks Are Moving the Most Today: Nvidia, Tesla, Autodesk, General Mills, Signet, HealthEquity, and More",
        "id": 133240129,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "These Stocks Are Moving the Most Today: Nvidia, Tesla, Autodesk, General Mills, Signet, HealthEquity, and More",
        "url": "https://finnhub.io/api/news?id=2a0985dadcf68508687f639d547c84ae4d29208bda6e7afefebcd028c017b92d"
    },
    {
        "category": "company",
        "datetime": 1742315760,
        "headline": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
        "id": 133242969,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=d99c93615a2ae5f420b5bcc65bf0b109f031b85b9d4c162c59e39c5771bf145b"
    },
    {
        "category": "company",
        "datetime": 1742301600,
        "headline": "Dividend Income: Lanny's February 2025 Summary",
        "id": 133230615,
        "image": "",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=96254f82b04f4fa52f3d90b4b63f1b9618a359eb435b95d2add8977c4b53ce4b"
    },
    {
        "category": "company",
        "datetime": 1742292917,
        "headline": "Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies",
        "id": 133219797,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "We're proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to operate responsibly and empower our employees to help...",
        "url": "https://finnhub.io/api/news?id=c04e65df8b624955e0b7d551b32d4995ee838cba37ebbe16309b1cf6a40b9238"
    },
    {
        "category": "company",
        "datetime": 1742147002,
        "headline": "Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally",
        "id": 133200276,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189074690/image_2189074690.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Gilead's dominance in HIV faces Medicare pricing challenges, limiting growth.",
        "url": "https://finnhub.io/api/news?id=936b31d0db50114432ca9f4c8c68f7ba52a8a984ba5567edf033fffa26f6a1d2"
    },
    {
        "category": "company",
        "datetime": 1741966235,
        "headline": "Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?",
        "id": 133185352,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=82271ce54ea5345b9142c7d260fc5faf0b5c2e296a6299fa7ec4c963996eda9d"
    },
    {
        "category": "company",
        "datetime": 1741950669,
        "headline": "Gilead Sciences - Women's History Month Celebrated With Its Team",
        "id": 133169355,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her approach to developing new medicines and to bringing...",
        "url": "https://finnhub.io/api/news?id=4c87f33764da6f2d390c28fd20538a91aead4809c676537aca1943e6faa2b938"
    },
    {
        "category": "company",
        "datetime": 1741898461,
        "headline": "CRISPR Therapeutics: An Uninspiring Start For Casgevy",
        "id": 133165247,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/113456532/image_113456532.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious \"Hold\" within a barbell portfolio.",
        "url": "https://finnhub.io/api/news?id=774ffbfb9ba9f0ea1819e4599c214d421107e388e57de809a7ebbbf22c59949c"
    },
    {
        "category": "company",
        "datetime": 1741885676,
        "headline": "Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds",
        "id": 133185353,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town in [\u2026]",
        "url": "https://finnhub.io/api/news?id=6244ef2070ffec6510ac57ae72f45801055ea7e4b87544dc9c976b6f4d5cc7a4"
    },
    {
        "category": "company",
        "datetime": 1741880408,
        "headline": "GILD vs. VRTX: Which Stock Is the Better Value Option?",
        "id": 133185354,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "GILD vs. VRTX: Which Stock Is the Better Value Option?",
        "url": "https://finnhub.io/api/news?id=525462baf97cedb30694019df10579d06c99d166a081e7f12a22589e2e566f2e"
    },
    {
        "category": "company",
        "datetime": 1741879829,
        "headline": "Gilead (GILD) Up 10.3% Since Last Earnings Report: Can It Continue?",
        "id": 133185355,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=f4f5ba28378e34cb23139f6521ee9a428121df1b6b9767a0c58b1f15fb53e3d4"
    },
    {
        "category": "company",
        "datetime": 1741870813,
        "headline": "Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It",
        "id": 133185356,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.",
        "url": "https://finnhub.io/api/news?id=80375b804cb141999b51d7adc2cc24a64d0f8d5aa714c4b5c8349fdf1d86abd9"
    },
    {
        "category": "company",
        "datetime": 1741870680,
        "headline": "Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More",
        "id": 133185357,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "TSVT and PTGX are in the spotlight this week following an acquisition agreement and study data, respectively.",
        "url": "https://finnhub.io/api/news?id=6519bab17e273ef85c89ff51b950111014b85fc5e1c47175413fe535cb4ddaca"
    },
    {
        "category": "company",
        "datetime": 1741806000,
        "headline": "GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive",
        "id": 133185358,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.",
        "url": "https://finnhub.io/api/news?id=164329f7dec41ecf2bd4db43d8d0bb9078739234f2373c6ec2d0a86bd1b96e58"
    },
    {
        "category": "company",
        "datetime": 1741803386,
        "headline": "Analyst Says Gilead Sciences (GILD) is a \u2018Big Liquid\u2019 Stock You Should Pay Attention To",
        "id": 133185359,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at where Gilead Sciences Inc (NASDAQ:GILD) stands against other top stocks Wall Street is discussing. Bill Strazzullo, Bell Curve Trading chief market strategist, said in a latest program on CNBC that the [\u2026]",
        "url": "https://finnhub.io/api/news?id=c714696a3d3c233409b58ad0a6d19472a87edef1e6acdc88ababbc566cb6bd3c"
    },
    {
        "category": "company",
        "datetime": 1741799824,
        "headline": "Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data",
        "id": 133185360,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment portfolio, highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial results for once-yearly PrEP injections in significant publications emphasized Gilead's innovative edge. Coupled with robust earnings in Q4 2024,...",
        "url": "https://finnhub.io/api/news?id=58de4e1d2f634c0e401facb3c3e8545123fec00785e2ea86f5f08715063f6be1"
    },
    {
        "category": "company",
        "datetime": 1741798525,
        "headline": "Gilead Presents New HIV Treatment And Cure Research Data",
        "id": 133185361,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is an ongoing Phase 3 study evaluating Biktarvy versus dolutegravir 50 mg (DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, F/TDF, DTG+F/TDF, in adults with HIV-1/HBV coinfection initiating treatment. Previously reported results demonstrated the efficacy of both antiretroviral regimens.",
        "url": "https://finnhub.io/api/news?id=3954db55b1b2fa236ae03fb1b560a682214b8ff209b662b85e5fcb1ea4727e75"
    },
    {
        "category": "company",
        "datetime": 1741785840,
        "headline": "The Zacks Analyst Blog Highlights Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas",
        "id": 133185362,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas are part of the Zacks top Analyst Blog",
        "url": "https://finnhub.io/api/news?id=7393b5a647ebcba634b440a3bc4d5f6562db57eb310d637af5fd4f9f47370be8"
    },
    {
        "category": "company",
        "datetime": 1741782600,
        "headline": "Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option",
        "id": 133185363,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). The new findings reflect a transformative portfolio and a rapidly advancing forward-looking pipeline focused on expanding choices and enhancing outcomes for those with HIV, while continuing to reach towards",
        "url": "https://finnhub.io/api/news?id=91c2f966381d25501327d6a435f3e526f48a23eaf410f90f479e5a3cb720e7ce"
    },
    {
        "category": "company",
        "datetime": 1741782221,
        "headline": "Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success",
        "id": 133185364,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "The company has already seen massive success with a twice-yearly version of lenacapavir PrEP for HIV.",
        "url": "https://finnhub.io/api/news?id=c7d3156563c49292c85b417646fde7e5c1112df6a486158a167f145ed51a92a0"
    },
    {
        "category": "company",
        "datetime": 1741782146,
        "headline": "First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet",
        "id": 133153092,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "FOSTER CITY - Gilead Sciences, Inc. today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1...",
        "url": "https://finnhub.io/api/news?id=51fc684a503324f825cc8ce1cce9544e25abd03aaf47898d7926f23a149faa69"
    },
    {
        "category": "company",
        "datetime": 1741729620,
        "headline": "These 3 Attractive Stocks Keep Cruising Higher",
        "id": 133185365,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Despite recent negativity, several stocks, including Verizon Communications, Gilead Sciences, and Alibaba, have shaken off the woes, showing stability and relative strength throughout the period.",
        "url": "https://finnhub.io/api/news?id=d61fceb7f03f611dc3b968fa152ec6d1ba377d420da7469e20cc87afb7aaf590"
    },
    {
        "category": "company",
        "datetime": 1741728555,
        "headline": "Tracking Renaissance Technologies 13F Portfolio - Q4 2024 Update",
        "id": 133140400,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2164745052/image_2164745052.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA. Read a portfolio update here.",
        "url": "https://finnhub.io/api/news?id=7ec5e1a10869fd2ac0edf332e5cc9731271a2844e308c8ff8479d01288fa561f"
    },
    {
        "category": "company",
        "datetime": 1741714620,
        "headline": "First Clinical Data for Gilead\u2019s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet",
        "id": 133185366,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "FOSTER CITY, Calif., March 11, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company\u2019s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). The data were presented during an oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) and were also published today in The",
        "url": "https://finnhub.io/api/news?id=bcd50b8ed47e9229cb10cfdd0d5f4df8ccaef14aca09c7bca782d63178f16c7d"
    },
    {
        "category": "company",
        "datetime": 1741702445,
        "headline": "Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)",
        "id": 133136377,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) Leerink Partners Global Healthcare Conference Call March 11, 2025 10:40 AM ETCompany ParticipantsCindy Perettie -...",
        "url": "https://finnhub.io/api/news?id=ef5c09d238447c271627bfe49d6df8ada7ba68917677fc1e207494de7a24802c"
    },
    {
        "category": "company",
        "datetime": 1741700400,
        "headline": "These 10 stocks beating the market\u2019s recent Trump slump have this in common",
        "id": 133136678,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "These 10 stocks beating the market\u2019s recent Trump slump have this in common",
        "url": "https://finnhub.io/api/news?id=e8383f6a57268bab0c9cf132cc1de00ab367c29c1676d860b3901c1a8d646442"
    },
    {
        "category": "company",
        "datetime": 1741698720,
        "headline": "Buy 5 Non-Tech High-Flying Nasdaq Stocks Amid Index's Recent Bloodbath",
        "id": 133185367,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "We have narrowed our search to five Nasdaq Composite-listed non-tech stocks that have provided double-digit returns year to date. These are: EXC, GILD, PAA, SRAD, CTAS.",
        "url": "https://finnhub.io/api/news?id=48ad993fb9f7f6e9a6f35d18632f239966d57578077327c7cbc5abe9266ec541"
    },
    {
        "category": "company",
        "datetime": 1741698125,
        "headline": "BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund",
        "id": 133136036,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148098716/image_2148098716.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.",
        "url": "https://finnhub.io/api/news?id=0a90bbc72c21544b52437a24252fdcd27158f61d0b5128e17ea6b2ed0058f641"
    },
    {
        "category": "company",
        "datetime": 1741683790,
        "headline": "Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks",
        "id": 133184494,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "As the craze of earnings season draws to a close, here\u2019s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN).",
        "url": "https://finnhub.io/api/news?id=9fe4a725567f0ded1bfde5503ad24daef9853559a131d4fedf9568a7ea220327"
    },
    {
        "category": "company",
        "datetime": 1741681200,
        "headline": "The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)",
        "id": 133185369,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks struggled due in part to concerns about how Robert F. Kennedy's nomination for Health and Human Services Secretary might impact the industry.  AppLovin (NASDAQ: APP) advanced 713%.  Palantir Technologies (NASDAQ: PLTR) advanced 340%.",
        "url": "https://finnhub.io/api/news?id=93b57b99b9cb9dcc4fc0ea2d744294bcfde18c7d9daca45653d1a68d93840d05"
    },
    {
        "category": "company",
        "datetime": 1741618920,
        "headline": "Zacks Investment Ideas feature highlights: Gilead Sciences and Johnson & Johnson",
        "id": 133185370,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences and Johnson & Johnson are part of the Zacks Investment Ideas article.",
        "url": "https://finnhub.io/api/news?id=56133c0c85049102226e2f8ffc42fd36aa9d04ec29653086dd06a53dd5894b16"
    },
    {
        "category": "company",
        "datetime": 1741614010,
        "headline": "Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?",
        "id": 133185371,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Here is how Gilead Sciences (GILD) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.",
        "url": "https://finnhub.io/api/news?id=1de9f640bb38f2d7335399aa282fed044fc657f06070b541c8b32c8c19559a20"
    },
    {
        "category": "company",
        "datetime": 1741394217,
        "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of March 9",
        "id": 133102197,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Read here for weekly updates on Dividend Champions, Contenders, and Challengers. Track dividend changes, ex-dividend dates, and upcoming pay dates.",
        "url": "https://finnhub.io/api/news?id=0c88e6b6649340df865b9b0c9db5ae959268a73935092926aa354a8a048ef754"
    },
    {
        "category": "company",
        "datetime": 1741189140,
        "headline": "Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out",
        "id": 134146993,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out",
        "url": "https://finnhub.io/api/news?id=3440ff10a59f58a05553b64b29e518edc846c32ab72cf2f47c6b2022112b2d7f"
    },
    {
        "category": "company",
        "datetime": 1741181460,
        "headline": "5 Big Biopharmaceutical Stocks That Are Finding Favor",
        "id": 133017083,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "5 Big Biopharmaceutical Stocks That Are Finding Favor",
        "url": "https://finnhub.io/api/news?id=26ee08ddf101d2a804ccb3de6ef47bdd041f08f4c18732bc711d2fb938484324"
    },
    {
        "category": "company",
        "datetime": 1741106160,
        "headline": "Gilead Sciences Inc. stock outperforms competitors despite losses on the day",
        "id": 132983404,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Gilead Sciences Inc. stock outperforms competitors despite losses on the day",
        "url": "https://finnhub.io/api/news?id=72ba371603efbaa42cc9c678fbbc51305b36de5102fb0ccbca1f9af6627cb6bd"
    },
    {
        "category": "company",
        "datetime": 1741097044,
        "headline": "Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript)",
        "id": 132979526,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) TD Cowen 45th Annual Healthcare Conference March 4, 2025 11:10 AM ETCompany ParticipantsJohanna Mercier - Chief...",
        "url": "https://finnhub.io/api/news?id=47b9149aed9c1330a236e4052204d1c01f5c8904e1ec07ec6152448d8b4a1991"
    },
    {
        "category": "company",
        "datetime": 1741020634,
        "headline": "On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks.",
        "id": 132973165,
        "image": "",
        "related": "GILD",
        "source": "DowJones",
        "summary": "On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks.",
        "url": "https://finnhub.io/api/news?id=ed88dfbcbe1408521bb94326eced6535d8664f011046dddec41b2092634a6bd6"
    },
    {
        "category": "company",
        "datetime": 1740726000,
        "headline": "Drug Stocks Are the New Safe Bet in a Shaky Market",
        "id": 132907806,
        "image": "",
        "related": "GILD",
        "source": "DowJones",
        "summary": "Drug Stocks Are the New Safe Bet in a Shaky Market",
        "url": "https://finnhub.io/api/news?id=9cbf52ef07edbc5bfcfb2610a217677b7f12f0522f3e65f5864ff7326854f3b8"
    },
    {
        "category": "company",
        "datetime": 1740610521,
        "headline": "Why Gilead Sciences Remains A Buy After A 40% Rally",
        "id": 132896295,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/492146371/image_492146371.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term investors. See more on GILD stock here.",
        "url": "https://finnhub.io/api/news?id=1582af67631cc15c84ec098d47f1c3e9752315ef00f6ae8ee73a59d809bc89ef"
    },
    {
        "category": "company",
        "datetime": 1740500160,
        "headline": "Healthcare Stocks Should Be Hurting. How the Sector Became This Year\u2019s Top Performer.",
        "id": 134149033,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Healthcare Stocks Should Be Hurting. How the Sector Became This Year\u2019s Top Performer.",
        "url": "https://finnhub.io/api/news?id=7af0a76e4c3cc91ed845fb7b6fcdd430eaac433ea3f560f461bea410da825c33"
    },
    {
        "category": "company",
        "datetime": 1740435780,
        "headline": "Hartford Equity Income Fund Q4 2024 Commentary",
        "id": 132867316,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2095584352/image_2095584352.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Hartford Equity Income Fund (I share) underperformed the Russell 1000 Value Index during the quarter. Read more here.",
        "url": "https://finnhub.io/api/news?id=f95c07e653005714d4816a7784c66ad729b2d2ab7264888ba8a672949ffd2bed"
    },
    {
        "category": "company",
        "datetime": 1740405780,
        "headline": "Hartford Dividend And Growth Fund Q4 2024 Commentary",
        "id": 132865261,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2095584352/image_2095584352.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Hartford Dividend and Growth Fund (I shares) underperformed the S&P 500 Index for the quarter. Read more here.",
        "url": "https://finnhub.io/api/news?id=7dc980509a36eac275b2142e4fca0e11820c26f6d268f82362164c22c1478a84"
    },
    {
        "category": "company",
        "datetime": 1740386043,
        "headline": "European Medicines Agency Validates Gilead\u2019s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention",
        "id": 132863358,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "\u2013 One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries \u2013\u2013 Both Applications Will Be Assessed in...",
        "url": "https://finnhub.io/api/news?id=aacf2aeb8946b8845ed4cb0d80f4138f41201731a7fab4ba03f78d18236e85ba"
    },
    {
        "category": "company",
        "datetime": 1740069183,
        "headline": "Gilead\u2019s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis",
        "id": 132823335,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "\u2013 Now Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area \u2013\u2013 First and Only Treatment That Achieved...",
        "url": "https://finnhub.io/api/news?id=006216ccb6f3d440e6234ccd0e4d394fbb5a9230ce233f7ea79811fd95359852"
    },
    {
        "category": "company",
        "datetime": 1740035620,
        "headline": "Disount To Net Cash For A Promising CAR-T Company",
        "id": 132798424,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/525231584/image_525231584.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Galapagos NV\u00e2\u0080\u0099s split could unlock value despite short-term share decline. Learn why GLPG stock\u00e2\u0080\u0099s strategic focus offers upside but risks in the CAR-T space.",
        "url": "https://finnhub.io/api/news?id=1b2940149a0d46e5537bee9d1b0731550bb1593ad000bae24053a8c21939af84"
    },
    {
        "category": "company",
        "datetime": 1739981284,
        "headline": "Gilead Sciences to Present at Upcoming Investor Conferences",
        "id": 132790925,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "Gilead Sciences, Inc. announced today that its executives will be speaking at the following investor conferences:TD Cowen Annual Health Care Conference on Tuesday, March 4 at 11:10 AM Eastern...",
        "url": "https://finnhub.io/api/news?id=6e102cda5e45c88588f4920a6315ec01030711f400510c0d482df3b3d800c414"
    },
    {
        "category": "company",
        "datetime": 1739963106,
        "headline": "The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease",
        "id": 132785238,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "Take a spin through the latest in Gilead's science and innovation in our new series, The Centrifuge Sessions. Today we sit down with D. Barry Crittenden, Executive Director of Clinical Development, to...",
        "url": "https://finnhub.io/api/news?id=dd7a5046857ac93df8aca61ea1db44fcab463debdbb1ace879e549334551d6bc"
    },
    {
        "category": "company",
        "datetime": 1739962740,
        "headline": "BNY Mellon Global Equity Income Fund Q4 2024 Commentary",
        "id": 132786828,
        "image": "",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=4c554206834be7e0f26387b96cbd838e08041f83bb259a02a948f544bd94109b"
    },
    {
        "category": "company",
        "datetime": 1739952600,
        "headline": "My Dividend Stock Portfolio: New January Dividend Record - 100 Holdings With 14 Buys",
        "id": 132784079,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "January hits new highs with $814 in dividend income, up 21% Y/Y. See how BDC investments drive growth toward $11,000 annual dividends.",
        "url": "https://finnhub.io/api/news?id=5455f567381019beddc413e7e5eb783a45482cdef95f6ee343bcfd391c577c6d"
    },
    {
        "category": "company",
        "datetime": 1739884338,
        "headline": "Nurix Therapeutics: A Story To Monitor",
        "id": 132779003,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281832252/image_1281832252.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated CLL patients, click for more on NRIX.",
        "url": "https://finnhub.io/api/news?id=60388fed80d28cbd7b31c5f3a4d32f3030b942e762d20c7a6eb37dfea4cff31a"
    },
    {
        "category": "company",
        "datetime": 1739872020,
        "headline": "Gilead Gets FDA Priority Review of Twice-Yearly Shot to Prevent HIV",
        "id": 132770781,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Gilead Gets FDA Priority Review of Twice-Yearly Shot to Prevent HIV",
        "url": "https://finnhub.io/api/news?id=4ba1ed12a9c346f50e99c03f5e242f916a8a388aae29d2abcd162f85f3cfd766"
    },
    {
        "category": "company",
        "datetime": 1739817360,
        "headline": "Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?",
        "id": 132766586,
        "image": "https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there is more room for growth and recommend the stock to investors.",
        "url": "https://finnhub.io/api/news?id=263c82875c6ea1ec9ff53ef3136ed9d477435a111266621eb1bd68f77594dfef"
    },
    {
        "category": "company",
        "datetime": 1739803216,
        "headline": "Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?",
        "id": 132766587,
        "image": "https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
        "url": "https://finnhub.io/api/news?id=2f50924c35a2ce3937ac1dff859115fd660cde578f82fd4e3769aa1629a94f77"
    },
    {
        "category": "company",
        "datetime": 1739801714,
        "headline": "Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?",
        "id": 132766588,
        "image": "https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
        "url": "https://finnhub.io/api/news?id=f7037a0034c24260e441542d116996a58d3656fcd85db0aac6b097b4b9b909d6"
    },
    {
        "category": "company",
        "datetime": 1739797036,
        "headline": "Gilead Sciences, Inc. (GILD): A Bull Case Theory",
        "id": 132766589,
        "image": "https://media.zenfs.com/en/insidermonkey.com/eac1823d9f28febc8d255a13ab8f3e5e",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "We came across a bullish thesis on Gilead Sciences, Inc. (GILD) on Substack by Disruptive analytics. In this article, we will summarize the bulls\u2019 thesis on GILD. Gilead Sciences, Inc. (GILD)\u2019s share was trading at $104.08 as of Feb 14th. GILD\u2019s trailing and forward P/E were 273.89 and 13.37 respectively according to Yahoo Finance. Gilead Sciences (GILD) [\u2026]",
        "url": "https://finnhub.io/api/news?id=c0a5d6ae8a0e0bf795293e19b1e67149f161a49241002ef8f805708abfa43bc1"
    },
    {
        "category": "company",
        "datetime": 1739757520,
        "headline": "Coca-Cola, Home Depot And Walmart Among 10 Companies To Announce Dividend Increases In Second Half Of February",
        "id": 132743511,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2179041715/image_2179041715.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "February\u00e2\u0080\u0099s dividend increases slow, but major companies like Coca-Cola and Walmart are still raising dividends. Find out which 10 companies are increasing payouts.",
        "url": "https://finnhub.io/api/news?id=59ab27c195251cd9e5c1d7021f94f47974e74b4b8f113135e9ddea8acec9d76f"
    },
    {
        "category": "company",
        "datetime": 1739623793,
        "headline": "Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79",
        "id": 132766590,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "The board of Gilead Sciences, Inc. ( NASDAQ:GILD ) has announced that the dividend on 28th of March will be increased...",
        "url": "https://finnhub.io/api/news?id=19dcc043004339d7215a110edf746384210248751db8418feecd9e6e9c18977d"
    },
    {
        "category": "company",
        "datetime": 1739602800,
        "headline": "Beat The S&P 500 With An ETF Portfolio That Grows Dividend Income",
        "id": 132716233,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253985609/image_1253985609.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "A tax-efficient ETF strategy can beat the S&P 500. Read why this portfolio offers diversified exposure and superior free cash flow for steady returns.",
        "url": "https://finnhub.io/api/news?id=fd9619f5eae4ab84720d67e5cadaceac1523e1dfaa735438905fb4bbfe48d558"
    },
    {
        "category": "company",
        "datetime": 1739580268,
        "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of February 16",
        "id": 132715008,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Read here to learn more on the latest weekly updates on dividend activity for Dividend Champions, Contenders, and Challengers.",
        "url": "https://finnhub.io/api/news?id=490ff37d6c0d3f2fd85b8b979e275b2f4324654e0fe342d66da58a1b61e1d4e0"
    },
    {
        "category": "company",
        "datetime": 1739551020,
        "headline": "Gilead Sciences Inc. stock underperforms Friday when compared to competitors",
        "id": 132722830,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Gilead Sciences Inc. stock underperforms Friday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=441b30babfd5d071ab6f03907ad2bbecbe75f1169dc123532af139779e3259df"
    },
    {
        "category": "company",
        "datetime": 1739480280,
        "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q4 2024 Commentary",
        "id": 132709614,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172483014/image_172483014.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "The Portfolio returned -10.75% (gross) and the MSCI World Health Care IndexSM returned -11.32%. Read more here.",
        "url": "https://finnhub.io/api/news?id=8d306981723ae6baaa27a41df72a2ad77528d2ff9fae45eee20d34b6483d2dcd"
    },
    {
        "category": "company",
        "datetime": 1739469720,
        "headline": "Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance",
        "id": 132766591,
        "image": "https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "GILD and BIIB are in the spotlight this week on fourth-quarter earnings release and outlook for 2025.",
        "url": "https://finnhub.io/api/news?id=eb023a3a1911ffb93abd81bdba2825ddf349efab23179a2e1e56822e7fa4dc85"
    },
    {
        "category": "company",
        "datetime": 1739458214,
        "headline": "Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?",
        "id": 132766592,
        "image": "https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
        "url": "https://finnhub.io/api/news?id=3cc3b836174418194cf399efc7f9c7386a005e75c8228e2aa811484a5d7d9e9a"
    },
    {
        "category": "company",
        "datetime": 1739440937,
        "headline": "3 US Stocks Estimated Up To 48.1% Undervalued Based On Intrinsic Value Estimates",
        "id": 132766593,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/4225c685274ad9a59115d9af5c5b916f",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "As U.S. markets navigate the complexities of rising inflation and fluctuating interest rates, investors are increasingly focused on identifying opportunities that may be undervalued in the current economic climate. In this context, understanding a stock's intrinsic value becomes crucial for discerning which investments might offer potential value despite broader market volatility.",
        "url": "https://finnhub.io/api/news?id=69e0ecfcae495519115b2297336f6bdaab07af6622e548aee675455df3d0dc7b"
    },
    {
        "category": "company",
        "datetime": 1739396181,
        "headline": "S&P 500 Gains and Losses Today: CVS Stock Jumps as Pharmacy Segment Delivers Growth",
        "id": 132741040,
        "image": "https://www.investopedia.com/thmb/kx3okyqVxpGOulzinzdYjjcLxU8=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1767478157-79ec5e21290e4cb99cdedb1850a89500.jpg",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "The S&P 500 dropped 0.3% on Wednesday, Feb. 12, as hotter-than-expected inflation data in the January CPI report weighed on the interest rate outlook.",
        "url": "https://finnhub.io/api/news?id=117f340922c1c4dd3c42db401d2f99288dc372f3213882f6bec8a73bc222569c"
    },
    {
        "category": "company",
        "datetime": 1739395089,
        "headline": "Gilead Hits Buy Zone After Obliterating Fourth-Quarter Expectations",
        "id": 132766595,
        "image": "https://media.zenfs.com/en/ibd.com/220b994ba82b273562061a4d57daf68d",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead stock surged to a buy zone Wednesday after the company obliterated fourth-quarter forecasts and issued an upbeat profit outlook.",
        "url": "https://finnhub.io/api/news?id=309c093567825b5bb4a32970532acfe5a1aca7bd64b1235488539b82afa97668"
    },
    {
        "category": "company",
        "datetime": 1739392800,
        "headline": "Janus Henderson Global Life Sciences Fund Q4 2024 Commentary",
        "id": 132698753,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205585/image_1322205585.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=10b10afe2a805029d7ce2f9c8b1ec10ce14300270ce9d50ee7971586c5474449"
    },
    {
        "category": "company",
        "datetime": 1739386174,
        "headline": "Why Gilead Sciences (GILD) Stock Is Trading Up Today",
        "id": 132766596,
        "image": "https://s.yimg.com/ny/api/res/1.2/lyWUZYMtpQ1Jlvi5PE5Bbg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue, EPS, and adjusted operating income estimates. Revenue grew 6%, driven by a 16% increase in HIV product sales and supported by strength in oncology and liver disease products. The momentum is expected to continue into the next year, as full-year EPS guidance surpassed Wall Street estimates, while sales gu",
        "url": "https://finnhub.io/api/news?id=f35d5c1dbb974688849a745afa4f35fbc1bb78d3a699d25ab8bc19be5963a918"
    },
    {
        "category": "company",
        "datetime": 1739380867,
        "headline": "Why Gilead Sciences Stock Is Jumping Today",
        "id": 132766597,
        "image": "https://g.foolcdn.com/editorial/images/807456/scientists-happy.jpg",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Shares of Gilead Sciences (NASDAQ: GILD) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year financial results following market close on Tuesday.  Gilead reported fourth-quarter revenue of $7.6 billion, up 6% year over year.  It posted earnings per share (EPS) of $1.42 based on generally accepted accounting principles (GAAP), reflecting a year-over-year increase of roughly 25%.",
        "url": "https://finnhub.io/api/news?id=96ca7530c2554863979037c8dfe7901e824356f6c9af528a0b786bbe33128c96"
    },
    {
        "category": "company",
        "datetime": 1739371211,
        "headline": "Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy?",
        "id": 132766598,
        "image": "https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
        "url": "https://finnhub.io/api/news?id=d08622a44b23d83e12d434b950378d96a90448cd16991371a605b9da466980d5"
    },
    {
        "category": "company",
        "datetime": 1739366760,
        "headline": "GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance",
        "id": 132766599,
        "image": "https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences' Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is trading up.",
        "url": "https://finnhub.io/api/news?id=054675635c42796bcf7b8d52ff9186e3456eba9c6b18e3a8388131113cc46489"
    },
    {
        "category": "company",
        "datetime": 1739364645,
        "headline": "Q4 2024 Gilead Sciences Inc Earnings Call",
        "id": 132766600,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Q4 2024 Gilead Sciences Inc Earnings Call",
        "url": "https://finnhub.io/api/news?id=83383a17dc20d42822cd29c984ab9b300b3463fbc72492611028370b04dce21a"
    },
    {
        "category": "company",
        "datetime": 1739362380,
        "headline": "Medicare Reform to Flatten Gilead's Booming HIV Sales",
        "id": 132684217,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Medicare Reform to Flatten Gilead's Booming HIV Sales",
        "url": "https://finnhub.io/api/news?id=a4448a6fdd4a85cbf3ad868921b127b13a10665dd951d59ac84e15b4f9ff7ebb"
    },
    {
        "category": "company",
        "datetime": 1739357172,
        "headline": "Trending tickers: Intel, Alibaba, Super Micro, Lyft and Barratt Redrow",
        "id": 132766601,
        "image": "https://s.yimg.com/ny/api/res/1.2/NFzxUv2TMOR0Ic9GQEXNbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-11/c152a940-9c88-11ef-b7ff-54d6c513abc1",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "The latest investor updates on stocks that are trending on Wednesday.",
        "url": "https://finnhub.io/api/news?id=c3de888da878fbb24e22bfe39a3b4dd5177652b2b2225c78932f02926a7d0847"
    },
    {
        "category": "company",
        "datetime": 1739357049,
        "headline": "Gilead Tops Buy Zone After Obliterating Fourth-Quarter Expectations",
        "id": 132684197,
        "image": "",
        "related": "GILD",
        "source": "DowJones",
        "summary": "Gilead Tops Buy Zone After Obliterating Fourth-Quarter Expectations",
        "url": "https://finnhub.io/api/news?id=afef3958cc57f29626ccf4231b9996c106f7456685eb65ed876548610c6e67fa"
    },
    {
        "category": "company",
        "datetime": 1739348729,
        "headline": "Gilead Sciences: Strong Q4 Results And Huge Progress In HIV",
        "id": 132679415,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1209171665/image_1209171665.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price target for GILD stock.",
        "url": "https://finnhub.io/api/news?id=53b543ed9c37a15d01fc7679d897fef9d9f0b1bfd8e1388f231e78091f5ad895"
    },
    {
        "category": "company",
        "datetime": 1739344311,
        "headline": "Gilead Sciences Inc (GILD) Q4 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...",
        "id": 132766602,
        "image": "https://media.zenfs.com/en/us.finance.gurufocus/84a579dd14fa3db57968682e27407e42",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences Inc (GILD) reports robust sales growth, driven by HIV and oncology advancements, despite challenges from Veklury sales decline and Medicare reforms.",
        "url": "https://finnhub.io/api/news?id=62068bb33baf10d371048107dcc873da63df869a263fb317981ca1ac512f2bcb"
    },
    {
        "category": "company",
        "datetime": 1739330123,
        "headline": "Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript",
        "id": 132766603,
        "image": "https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "GILD earnings call for the period ending December 31, 2024.",
        "url": "https://finnhub.io/api/news?id=5fca3ab0669d30ab9d49bcdf6acdb3707d20e09f1689c38dc29eb778a8866db5"
    },
    {
        "category": "company",
        "datetime": 1739320204,
        "headline": "Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates",
        "id": 132766604,
        "image": "https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
        "url": "https://finnhub.io/api/news?id=5717c7fc08cb3a57c7568e9c7bde9303f99f88137291621b97f8a4b303b1e00a"
    },
    {
        "category": "company",
        "datetime": 1739311805,
        "headline": "Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates",
        "id": 132766605,
        "image": "https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead (GILD) delivered earnings and revenue surprises of 13.77% and 7.27%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
        "url": "https://finnhub.io/api/news?id=e27f77bce6c47da48a73dc0823c6d5f0f731a8e5cbed2a7ec04bd6c616415c85"
    },
    {
        "category": "company",
        "datetime": 1739306532,
        "headline": "Gilead Sciences, Inc. 2024 Q4 - Results - Earnings Call Presentation",
        "id": 132677136,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "The following slide deck was published by Gilead Sciences, Inc.",
        "url": "https://finnhub.io/api/news?id=108a4c3dfef394863a462589c5e982cc3eec047490441f52fdac9cedfb286cd7"
    },
    {
        "category": "company",
        "datetime": 1739306437,
        "headline": "Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript",
        "id": 132677138,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ETCompany ParticipantsJacquie Ross - SVP, Treasury &amp;...",
        "url": "https://finnhub.io/api/news?id=f88bc1af0395fd1848c18d558bb8fa9c2d82cce836878ec2cb98936f8a44debf"
    },
    {
        "category": "company",
        "datetime": 1739290080,
        "headline": "Gilead Beats Earnings Estimates on Strong HIV Sales. The Stock Is Rising.",
        "id": 134149036,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Gilead Beats Earnings Estimates on Strong HIV Sales. The Stock Is Rising.",
        "url": "https://finnhub.io/api/news?id=f40787dc07e3b82cb29e5410ef6cc2153ce92dcb34dc552e925332e75a3cf2aa"
    },
    {
        "category": "company",
        "datetime": 1739289720,
        "headline": "Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised",
        "id": 132684219,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised",
        "url": "https://finnhub.io/api/news?id=97285ecd7479d14351461180684a93543117126d6d7a7163b37ad85f18362214"
    },
    {
        "category": "company",
        "datetime": 1739243078,
        "headline": "Gilead Sciences: Diversification Strategy Not Derisked Enough Yet",
        "id": 132656676,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my recommendation for GILD stock.",
        "url": "https://finnhub.io/api/news?id=6ca7d2da2fa08baa5542c2235e7acee5730fafed01109fb5f717fb80f89bba9f"
    },
    {
        "category": "company",
        "datetime": 1739239800,
        "headline": "Q4 Earnings Growth Continues To Climb Despite Mixed Tech Results",
        "id": 132656521,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1084171152/image_1084171152.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Q4 S&P 500 EPS growth expected to come in at 16.4%, the highest growth rate in three years. Read more here.",
        "url": "https://finnhub.io/api/news?id=8dcc76797f66a6433bc633aae8fb6f8a6380ea23097b3c694328c722121c836e"
    },
    {
        "category": "company",
        "datetime": 1739205407,
        "headline": "Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming",
        "id": 132638958,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192903839/image_2192903839.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Explore the potential of Ideaya Biosciences, Inc.'s Darovasertib in treating uveal melanoma as a monotherapy and in combination therapy. Click for more on IDYA.",
        "url": "https://finnhub.io/api/news?id=58cf062de0b62a43333be43bed26cf79b7dd57ae23ace8f7c108b7af4f624e8e"
    },
    {
        "category": "company",
        "datetime": 1739082525,
        "headline": "Wall Street Week Ahead",
        "id": 132626374,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165462299/image_2165462299.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Stay informed on upcoming economic data releases and earnings reports with Wall Street Breakfast, now available as a daily podcast on Seeking Alpha, iTunes,...",
        "url": "https://finnhub.io/api/news?id=071849bcbb73239bb7f241dcbbddc19f39b46050c2c90626c9f5f1da36484d98"
    },
    {
        "category": "company",
        "datetime": 1739012400,
        "headline": "Consumer Companies In Focus Next Week As McDonald's, Coca-Cola, Unilever Report Earnings",
        "id": 132603561,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "This week's earnings releases include consumer companies. A number of IPOs are set to begin trading and Jan. CPI data will be released on Wednesday. See more.",
        "url": "https://finnhub.io/api/news?id=525fb5c6227a36042e04ceb1fde2894a5f63eb685316ff76ecaa664ae5f1af29"
    },
    {
        "category": "company",
        "datetime": 1738858620,
        "headline": "Amgen Stock Has Surged. Here\u2019s Where It\u2019s Headed Next.",
        "id": 134148466,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Amgen Stock Has Surged. Here\u2019s Where It\u2019s Headed Next.",
        "url": "https://finnhub.io/api/news?id=903c377631a8e3dc89ac1a005a7711204e5e2613b0a33eb4ae8d90708713e809"
    },
    {
        "category": "company",
        "datetime": 1738720500,
        "headline": "J.P. Morgan Healthcare Conference 2025: Healthcare's Roadmap For The Year Ahead",
        "id": 132559368,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/956800254/image_956800254.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Major deals, including Johnson & Johnson\u00e2\u0080\u0099s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly $1T in industry financial capacity. Read more here.",
        "url": "https://finnhub.io/api/news?id=219da7f2b4534954405d56142bfd8fa2b7e3bf9f3d5cf0ec4011110a20f106f1"
    },
    {
        "category": "company",
        "datetime": 1738601788,
        "headline": "Gilead: Strong Sales Growth Remains With Veklury And Beyond",
        "id": 132539269,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195031759/image_2195031759.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success. Click for my GILD stock update.",
        "url": "https://finnhub.io/api/news?id=86ba1fba3a3471e5e26dba20a1ef62ba639343a47ffbee586b4f9587031677fc"
    },
    {
        "category": "company",
        "datetime": 1738224070,
        "headline": "Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications",
        "id": 132499009,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business valueTEANECK, N.J., Jan. 30, 2025 /PRNewswire/ -- Cognizant\u00a0 has announced an expansion of...",
        "url": "https://finnhub.io/api/news?id=15851945fbde8e867304f2c11a59d424e5a7bb12b8c0c0c57677dc6e73da9ec5"
    },
    {
        "category": "company",
        "datetime": 1738080364,
        "headline": "Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025",
        "id": 132488018,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "Gilead Sciences, Inc. announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on Tuesday, February 11, 2025, after the market closes. At 4:30...",
        "url": "https://finnhub.io/api/news?id=09f47ad946ed9ce8e54b0a14d784f7b0972e7ce8875d202c0e0aec14f3c277ff"
    },
    {
        "category": "company",
        "datetime": 1737995820,
        "headline": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains",
        "id": 132524379,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains",
        "url": "https://finnhub.io/api/news?id=632ea56840beade81d45ea2d37b5029f181eae599a78c870f18400cfe9c89180"
    },
    {
        "category": "company",
        "datetime": 1737792000,
        "headline": "5 Best CEFs This Month For Nearly 10% Yield (January 2025)",
        "id": 132468888,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310121198/image_1310121198.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Discover high-yield closed-end funds for income investors with reasonable total returns. Click for our process of winnowing out the best CEFS this month.",
        "url": "https://finnhub.io/api/news?id=197c5be575be03a4b9586b3090506ccae90f12a685d42c55c0010fb160219701"
    },
    {
        "category": "company",
        "datetime": 1737639382,
        "headline": "AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating",
        "id": 132449871,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429764/image_107429764.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company\u00e2\u0080\u0099s future looks bright.",
        "url": "https://finnhub.io/api/news?id=b0bffa5a9ae5c47a255e185aa2cf65897e628d26de0c5f6cfe30db3a2a88b556"
    },
    {
        "category": "company",
        "datetime": 1737611045,
        "headline": "Tango Therapeutics: Chance For A Short Squeeze",
        "id": 132447524,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2183545745/image_2183545745.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Explore more details here.",
        "url": "https://finnhub.io/api/news?id=4235307b72327f9330318ffcd7ffac1380ae8cc0a672c15b8eec1b2e0d0ad9b0"
    },
    {
        "category": "company",
        "datetime": 1737598920,
        "headline": "Dodge & Cox Balanced Fund Q4 2024 Shareholder Letter",
        "id": 132446540,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/917884914/image_917884914.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "The S&P 500 Index rose by 26.3% in 2023 and posted a 25.0% return in 2024, marking its largest consecutive annual gains since 1998. Read more here.",
        "url": "https://finnhub.io/api/news?id=97d7d2711a0bf68b39f810b96c40aeeb911d9207c46cc97a77dbdf06d2dbc1f1"
    },
    {
        "category": "company",
        "datetime": 1737124244,
        "headline": "Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI +",
        "id": 132416419,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1446170353/image_1446170353.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Discover investment opportunities in lesser-covered stocks like Arcus Biosciences, Sarepta Therapeutics, and Edison International.",
        "url": "https://finnhub.io/api/news?id=f3a594f5d198bb855d7b83442c2eb12200ba4157c8ce166395e1c27435dc20c9"
    },
    {
        "category": "company",
        "datetime": 1737007436,
        "headline": "Tempering Positive Sentiment Of AI In Biotech",
        "id": 132404884,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163707266/image_2163707266.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore more details here.",
        "url": "https://finnhub.io/api/news?id=cd2ce10465b2022ad38901994024c990f366b0e2333aac6670be174216a19808"
    },
    {
        "category": "company",
        "datetime": 1736955880,
        "headline": "Gilead Sciences, US government settle patent case over HIV prevention drugs",
        "id": 132401336,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court....",
        "url": "https://finnhub.io/api/news?id=d9f648a3660b754217d552404855621f99dbf505d58996ff58d4dc17ad649989"
    },
    {
        "category": "company",
        "datetime": 1736949664,
        "headline": "Gilead Sciences : Statement on Successful Resolution with U.S. Department of Justice and the Department of Health and Human Services on Patents",
        "id": 132400969,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "Foster City, Calif., January 15, 2025 - Gilead Sciences, Inc. today announced it has reached a final settlement agreement with the U.S. Department of Justice and the U.S. Department of Health and...",
        "url": "https://finnhub.io/api/news?id=6c89c70658c1a821f58e78172be99434f5dafa23e810aef8a7189b17b7208ab8"
    },
    {
        "category": "company",
        "datetime": 1736925600,
        "headline": "ClearBridge Value Fund Q4 2024 Commentary",
        "id": 132399220,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Strategy outperformed its Russell 1000 Value benchmark during 4Q, as positive contributions from stock selection and sector allocation effects contributed to relative performance.",
        "url": "https://finnhub.io/api/news?id=16104d7a68c2939ee98b902963633ee224985f62212a98b4fd4a0b33be489f73"
    },
    {
        "category": "company",
        "datetime": 1736895119,
        "headline": "Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025",
        "id": 132397136,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/470612294/image_470612294.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Read here for more on the potential of RCUS's combination therapies for various cancers, with promising Phase 3 trials and impressive overall survival rates in NSCLC.",
        "url": "https://finnhub.io/api/news?id=b30440ea1c28520941e479be92391b606ee486b00486df7f4834b15d22417496"
    },
    {
        "category": "company",
        "datetime": 1736791802,
        "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
        "id": 132390023,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1886168184/image_1886168184.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
        "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835"
    },
    {
        "category": "company",
        "datetime": 1736788189,
        "headline": "Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)",
        "id": 132389829,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) JPMorgan Annual Healthcare Conference Call January 13, 2025 2:15 PM ETCompany ParticipantsDaniel O'Day - Chairman and...",
        "url": "https://finnhub.io/api/news?id=ce0e32c57e5edb35bc1ea809bb1ededb3463e2f949c93a43ec0fca5e1c9fae73"
    },
    {
        "category": "company",
        "datetime": 1736599196,
        "headline": "Gilead, LEO Pharma partner to develop programs for inflammatory diseases",
        "id": 132378258,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases. The Danish company will be...",
        "url": "https://finnhub.io/api/news?id=adf5eaf3aa1a062c8f60e8701ba8d540e80152c6ffabccc0b695d21e67b91875"
    },
    {
        "category": "company",
        "datetime": 1736593263,
        "headline": "Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases",
        "id": 132377924,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "-- Strategic Partnership Strengthens Gilead\u2019s Inflammation Research Portfolio with the Addition of LEO Pharma\u2019s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders ---- Gilead...",
        "url": "https://finnhub.io/api/news?id=2076817123bd513dba0af03e2aafaef25b55ca7a1a455b8ca43b90e0152a444b"
    },
    {
        "category": "company",
        "datetime": 1736507294,
        "headline": "Poolbeg Pharma notes Gilead interest in Hookipa fundraise",
        "id": 132364454,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "Poolbeg Pharma PLC - London-based clinical stage biopharmaceutical firm - Updates on Gilead Sciences Inc's intentions regarding potential Hookipa Pharma Inc combination. Notes its intention to vote in...",
        "url": "https://finnhub.io/api/news?id=4f1067ac2c6025e62e37964d9f2887fd8a3819600bd077c17ba5b0e26a196754"
    },
    {
        "category": "company",
        "datetime": 1736487000,
        "headline": "Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point.",
        "id": 132407690,
        "image": "",
        "related": "GILD",
        "source": "DowJones",
        "summary": "Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point.",
        "url": "https://finnhub.io/api/news?id=84848e2e785c0ae5948f3425235062ed3b6c49daf113ab83ffda9a6fe1b18636"
    },
    {
        "category": "company",
        "datetime": 1736463620,
        "headline": "Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know",
        "id": 132357027,
        "image": "https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.",
        "url": "https://finnhub.io/api/news?id=ddf0fe58058b113b73bdf70bfa5efb16e2d0ac6e459784645348ce61110aefc0"
    },
    {
        "category": "company",
        "datetime": 1736412292,
        "headline": "Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation",
        "id": 132347250,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2152092840/image_2152092840.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like NX-5948.",
        "url": "https://finnhub.io/api/news?id=9f06a73ba77a30ccbaa704beaa0d91ca5181cad64d94592e296ca168a2816bc9"
    },
    {
        "category": "company",
        "datetime": 1736338605,
        "headline": "Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%",
        "id": 132315567,
        "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Galapagos (GLPG) said Wednesday that it plans to split into two entities, with a new company, or Spi",
        "url": "https://finnhub.io/api/news?id=456d2af91e4980863bf502b2f28c9b6223a4bd946a1b77cf8e6739d296e9b4e1"
    },
    {
        "category": "company",
        "datetime": 1736307720,
        "headline": "2024 Performance Review And Future Strategy",
        "id": 132312972,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "My 2024 picks outperformed the S&P 500, mainly due to Tesla, but small biotech firms lagged significantly. Learn more about my 2024 performance here.",
        "url": "https://finnhub.io/api/news?id=3922811a6b45756cc6f38314d6b95f2b71818045c9380e9535a68114ed74797a"
    },
    {
        "category": "company",
        "datetime": 1736306030,
        "headline": "Netherland's Galapagos to spin off innovative medicines business",
        "id": 132312765,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "-Dutch pharmaceutical firm Galapagos said on Wednesday it was planning to split into two listed entities by mid-2025, creating a new company focused on innovative medicines. Galapagos...",
        "url": "https://finnhub.io/api/news?id=89b5f627285cfa7a538a929f672f679bdfcc3baae423ae03f762d4d2e05c5b06"
    },
    {
        "category": "company",
        "datetime": 1736249479,
        "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
        "id": 132302431,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
        "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0"
    },
    {
        "category": "company",
        "datetime": 1736239932,
        "headline": "Poolbeg and Hookipa deal gets support from major stakeholder",
        "id": 132300019,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "Poolbeg Pharma PLC - London-based clinical stage biopharmaceutical firm - Confirms that Gilead Sciences Inc, a significant shareholder in Hookipa Pharma Inc, intends to vote in line with the Hookipa...",
        "url": "https://finnhub.io/api/news?id=03e8fd9967368b186bb53a8d347e0a02803bc48a7e2e38c928b5bd20093b01fe"
    },
    {
        "category": "company",
        "datetime": 1736175058,
        "headline": "Here\u2019s Why TCW Relative Value Large Cap Fund Exited its Position in Gilead Sciences (GILD)",
        "id": 132287306,
        "image": "https://media.zenfs.com/en/insidermonkey.com/bc0e73782debd64d3c678229ae2b05de",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "TCW Funds, an investment management company, released its \u201cTCW Relative Value Large Cap Fund\u201d Q3 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, U.S. and European indices reached all-time highs, fueled by optimism surrounding central bank easing, decreasing inflation, rising hopes for a soft landing, and stimulus [\u2026]",
        "url": "https://finnhub.io/api/news?id=e26004ac3201b02d81d8e871576a09e57c322bf7dea761d5f1fc47720705d7ff"
    },
    {
        "category": "company",
        "datetime": 1736086947,
        "headline": "Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold",
        "id": 132279730,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323875427/image_1323875427.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical indicators.",
        "url": "https://finnhub.io/api/news?id=d6e2bada4590e6cb2a8a0f476dcec9117273e7206fb178f2a5f2430389dceffb"
    },
    {
        "category": "company",
        "datetime": 1735945220,
        "headline": "Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors",
        "id": 132262156,
        "image": "https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day.",
        "url": "https://finnhub.io/api/news?id=95bba568ec8aba330780c53af7ad179e07710d1b648972062f87f320c2288e1b"
    },
    {
        "category": "company",
        "datetime": 1735876320,
        "headline": "Five Best: Novels in Letters",
        "id": 132246966,
        "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "1. I doubt Mary Shelley would ever forgive us for thinking Frankenstein was the monster of her novel, instead of the doctor rescued from icy waters on a voyage to the North Pole by one Capt. R. Walton.  While Walton slowly fades into the background and yields to this bright young scientist who reanimated human flesh, we the readers are drawn ever more deeply into this incredible tale, which is often credited as the first science-fiction novel.  Walton\u2019s act of kindness in the remote waters contrasts with the increasing cruelty of Victor\u2019s creation; by the end, the actions of both are characterized as central to our humanity.",
        "url": "https://finnhub.io/api/news?id=91be4571676c96f67b922abaeb5ed3e7e7b91222bc4965813992089eb37db22a"
    },
    {
        "category": "company",
        "datetime": 1735836060,
        "headline": "Gilead Sciences Inc. stock underperforms Thursday when compared to competitors",
        "id": 132325188,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Gilead Sciences Inc. stock underperforms Thursday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=8a102a2dd781ac0355242465f370a30389be7e964fc4bf75771320ec95370679"
    },
    {
        "category": "company",
        "datetime": 1735794736,
        "headline": "Poolbeg in early stage talks to combine with US biotech, Hookipa",
        "id": 132237024,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "Poolbeg Pharma PLC on Thursday said it was holding talks over an all-share combination with US-listed biopharmaceutical company Hookipa Pharma Inc.Under the proposed terms, shareholders in the...",
        "url": "https://finnhub.io/api/news?id=b467c04a42a0aa2f51d37e368a359e0a8800ff3e6eb3d7172637006443b2a155"
    },
    {
        "category": "company",
        "datetime": 1735640922,
        "headline": "Is Gilead Sciences, Inc. (GILD) the Best Dividend Stock of 2024?",
        "id": 132217666,
        "image": "https://s.yimg.com/ny/api/res/1.2/Hf3etvA0lJHPicbedFHsVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the Top 20 Dividend Stocks of 2024. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other dividend stocks. Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over [\u2026]",
        "url": "https://finnhub.io/api/news?id=30209ae2a9aa1a33c2ea86f950f7de0da3213700e4d839871c29344f461878dd"
    },
    {
        "category": "company",
        "datetime": 1735592501,
        "headline": "Is Gilead Sciences, Inc. (GILD) the Best Pharma Dividend Stock to Buy In 2024?",
        "id": 132206992,
        "image": "https://s.yimg.com/ny/api/res/1.2/Hf3etvA0lJHPicbedFHsVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but [\u2026]",
        "url": "https://finnhub.io/api/news?id=549089eb1e5274fbfdc6b8d6bb0d86f3d0769506ce712c4515d2183915d73f27"
    },
    {
        "category": "company",
        "datetime": 1735459200,
        "headline": "Gilead Buys $20.1 Million of Assembly Biosciences Stock",
        "id": 132195205,
        "image": "",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences bought nearly 950,000 more shares of antiviral-therapeutics developer Assembly as part of an amended investment and funding pact.",
        "url": "https://finnhub.io/api/news?id=2ba4f2fb25dc0595b874194d6778bac09e387383bd9b633b9c73506c5c2277ab"
    },
    {
        "category": "company",
        "datetime": 1735444277,
        "headline": "Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise",
        "id": 132193536,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1221948883/image_1221948883.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility. Explore more here.",
        "url": "https://finnhub.io/api/news?id=b7581c63c89c70b91bd2e8a91ae040607d1df7fee05f079ac8312f5509195372"
    },
    {
        "category": "company",
        "datetime": 1735296882,
        "headline": "Jim Cramer on Gilead Sciences, Inc. (GILD): \u2018I Don\u2019t Think The Business Is Worth As Much As The Stock Is Selling\u2019",
        "id": 132174562,
        "image": "https://s.yimg.com/ny/api/res/1.2/Hf3etvA0lJHPicbedFHsVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the Jim Cramer Talked About These 8 Stocks. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other stocks Jim Cramer talked about. Jim Cramer, host of Mad Money, recently shared some investment wisdom drawn from his four decades of [\u2026]",
        "url": "https://finnhub.io/api/news?id=d7673ae87eb7acce3a9664708ab15b06afcb3105e69c9d00fac7e9de7af25258"
    },
    {
        "category": "company",
        "datetime": 1735221613,
        "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
        "id": 132170140,
        "image": "https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.",
        "url": "https://finnhub.io/api/news?id=d348e33c56cda772baab6a7fad5989b5bd6ec8def4a2cfa64892ba367aa32cc9"
    },
    {
        "category": "company",
        "datetime": 1735205436,
        "headline": "PJP: Big Pharma Concentration Risks Amid Looming Confirmation Of RFK Jr.",
        "id": 132164310,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/832255342/image_832255342.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, and Merck. Read more here.",
        "url": "https://finnhub.io/api/news?id=d9924bfb15be4a412c5d30ffc3c153fb65db609d6f0526759c3ece67141e5e6e"
    },
    {
        "category": "company",
        "datetime": 1735144212,
        "headline": "Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock",
        "id": 132161281,
        "image": "https://media.zenfs.com/en/benzinga_79/2476474eaed16f81e0cca37298c9b424",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address unmet medical needs in the United States, Europe and internationally. It will report its Q4 2024 earnings on Feb. 11, 2025. ...",
        "url": "https://finnhub.io/api/news?id=1f684a418f2d9e0f807a2fe96c95d3c806c49cbf0591e366f719b8abee329307"
    },
    {
        "category": "company",
        "datetime": 1735058520,
        "headline": "Gilead Sciences Inc. stock rises Tuesday, still underperforms market",
        "id": 132148531,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Gilead Sciences Inc. stock rises Tuesday, still underperforms market",
        "url": "https://finnhub.io/api/news?id=f1ccda0dc5b6301d44897df1ddca457e4620fdffb29660e9bd33522428816191"
    },
    {
        "category": "company",
        "datetime": 1735049143,
        "headline": "Exploring Three High Growth Tech Stocks In The United States",
        "id": 132131745,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Over the last 7 days, the United States market has dropped 2.2%, yet it is up 24% over the past year with earnings forecasted to grow by 15% annually. In such dynamic conditions, identifying high growth tech stocks involves looking for companies with robust innovation and strong potential to capitalize on emerging trends in technology.",
        "url": "https://finnhub.io/api/news?id=067f5250d24631be5c283c85f944b4a82c0b31e832f3c77d816da7339bd8f056"
    },
    {
        "category": "company",
        "datetime": 1734985510,
        "headline": "Gilead Sciences Stock Today: Boost Your Return With This Covered Call Trade",
        "id": 132129650,
        "image": "https://media.zenfs.com/en/ibd.com/2048172cb2d6d6d78f5d808eb13ebdc6",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "If GILD stays below 100, the investor can continue selling call options until the shares get called away.",
        "url": "https://finnhub.io/api/news?id=d6e6565b406c248cf6690a82bcebbade7fda3e69f80369d276cb679cb753a174"
    },
    {
        "category": "company",
        "datetime": 1734961470,
        "headline": "Gilead Sciences (GILD) Made Big Announcements in Q3",
        "id": 132119459,
        "image": "https://media.zenfs.com/en/insidermonkey.com/bc0e73782debd64d3c678229ae2b05de",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the same can be downloaded here. Global markets were in solidly positive territory for the third straight quarter of 2024 despite geopolitical volatility. Polaris Global Equity Composite (net of fees) returned 6.86% in the quarter, compared to 6.46% [\u2026]",
        "url": "https://finnhub.io/api/news?id=9a1a08866939b23f5b70c869cc737654025a343e6a44a89a3d16a595b83b23fc"
    },
    {
        "category": "company",
        "datetime": 1734867920,
        "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of December 22",
        "id": 132110486,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.",
        "url": "https://finnhub.io/api/news?id=2b9a54d801d9e917deba72bfaf80315b8960a99f7b69af679c42bd8ee2844144"
    },
    {
        "category": "company",
        "datetime": 1734728700,
        "headline": "Gilead Sciences to Present at Upcoming Investor Conference",
        "id": 132084308,
        "image": "https://s.yimg.com/ny/api/res/1.2/1xvpAnuZJs3BSZ8Ir3NMOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/c540a71abfe7c2bbf6918ac2a7a02bca",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "FOSTER CITY, Calif., December 20, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:",
        "url": "https://finnhub.io/api/news?id=5c30fc451a9e9caf73cdc685c079002d0233d4af3aa9a8c28f22f25f10597927"
    },
    {
        "category": "company",
        "datetime": 1734717600,
        "headline": "Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?",
        "id": 132084309,
        "image": "https://media.zenfs.com/en/zacks.com/7de283b2224f57ff914c609b38092b2c",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.",
        "url": "https://finnhub.io/api/news?id=729fec09858569812296bc8ab7e6eebd399e17bd2011179d62db1865a57c1114"
    },
    {
        "category": "company",
        "datetime": 1734705609,
        "headline": "Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?",
        "id": 132076371,
        "image": "https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year.",
        "url": "https://finnhub.io/api/news?id=5e1dfe395dcfda5c21789f90290dd9e209f431651a50e2551524eccba10b4f7d"
    },
    {
        "category": "company",
        "datetime": 1734678300,
        "headline": "Impax US Sustainable Economy Fund Q3 2024 Commentary",
        "id": 132071401,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1580372641/image_1580372641.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "The Impax US International Sustainable Economy Fund outperformed its benchmark in the third quarter of 2024. Click here to read the full commentary. \n",
        "url": "https://finnhub.io/api/news?id=8a28b802c2856e0307a1310c4722d6042f42bed7622ae34e33bbab0f11ea0e0b"
    },
    {
        "category": "company",
        "datetime": 1734649218,
        "headline": "Gilead Sciences (GILD) Gains As Market Dips: What You Should Know",
        "id": 132060796,
        "image": "https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "In the most recent trading session, Gilead Sciences (GILD) closed at $91.09, indicating a +0.44% shift from the previous trading day.",
        "url": "https://finnhub.io/api/news?id=5b572ee58bc829f9ffa5a23e6ee8c63a26f5b8eed6c1c67c3c0c1ccda0d733e6"
    },
    {
        "category": "company",
        "datetime": 1734628843,
        "headline": "Gilead Sciences : Submits New Drug Application to U.S. Food and Drug Administration for Twice-Yearly Lenacapavir for HIV Prevention",
        "id": 132059051,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "Lenacapavir Named 2024 Breakthrough of the Year by Science Magazine Foster City, Calif., December 19, 2024 - Gilead Sciences, Inc. today announced the company completed New Drug...",
        "url": "https://finnhub.io/api/news?id=6eda77f7ea17e7f6aa8aa9bebe7fbe63b595f0636f25f05aeb3efc29a449b837"
    },
    {
        "category": "company",
        "datetime": 1734603976,
        "headline": "Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding",
        "id": 132052119,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "By Chris Wack Assembly Biosciences shares were up 19% at $16.01 after receiving an equity investment and accelerated funding from Gilead Sciences. Shares of the biotechnology company hit a...",
        "url": "https://finnhub.io/api/news?id=2b06be7ba7a6c8c98903312d86696d2f0ee0651a501363f378153febdb4d1ec7"
    },
    {
        "category": "company",
        "datetime": 1734597509,
        "headline": "Assembly Biosciences Gets $30.1 Million Equity Investment, Funding From Gilead",
        "id": 132050807,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "By Chris Wack Assembly Biosciences said it has received a $20.1 million equity investment from Gilead Sciences, along with $10 million in accelerated funding. Gilead is buying the additional...",
        "url": "https://finnhub.io/api/news?id=3c40b50dd38fc3a78f6cc7fd1a3c0b1dc3e64c4498e280232581af5263f1231e"
    },
    {
        "category": "company",
        "datetime": 1734596580,
        "headline": "Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead",
        "id": 132148535,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead",
        "url": "https://finnhub.io/api/news?id=f7fb1777042785a9e3516ec43819688e7b2572a9ef72937786807429fc67cd60"
    },
    {
        "category": "company",
        "datetime": 1734540120,
        "headline": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
        "id": 132148536,
        "image": "",
        "related": "GILD",
        "source": "MarketWatch",
        "summary": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=0480ee131a5655aa2cd1a97a83848c98215c62f68f52c6cdc2e2cccef4ed5f3d"
    },
    {
        "category": "company",
        "datetime": 1734534840,
        "headline": "GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer",
        "id": 132040765,
        "image": "https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication.",
        "url": "https://finnhub.io/api/news?id=95be068fd41508d350aff3f94026676ebaf3bc0082f74eba41dabb656371162c"
    },
    {
        "category": "company",
        "datetime": 1734531780,
        "headline": "Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains",
        "id": 132040766,
        "image": "https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.",
        "url": "https://finnhub.io/api/news?id=fc10686f69a3b951a15d97d3358a397ef18bcad2457c936da3f1e9be390c8bff"
    },
    {
        "category": "company",
        "datetime": 1734524449,
        "headline": "Gilead, Terray Therapeutics announce research collaboration",
        "id": 132040767,
        "image": "https://media.zenfs.com/en/tipranks_452/c7cc0ee97ba22ee31ce2f6fcf51d1f91",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Gilead (GILD) and Terray Therapeutics announced that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. Terray\u2019s tNova platform combines high-throughput chemical experimentation and computational analysis with a generative AI-driven drug discovery engine. Under the terms of the agreement, Terray will utilize the Terray tNova platform to discover and develop small molecule compounds against a set of targets se",
        "url": "https://finnhub.io/api/news?id=5c669ed52509dee4aa07677929facafb7d678c82626e7df5f19ce8aacbcf027b"
    },
    {
        "category": "company",
        "datetime": 1734523095,
        "headline": "Gilead and Terray link to develop small-molecule therapies",
        "id": 132040768,
        "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/Pharma-2-Gilead-Terry-Shutterstock_2483231331.jpg",
        "related": "GILD",
        "source": "Yahoo",
        "summary": "Terray is set to leverage its platform to identify and develop compounds for targets chosen by Gilead.",
        "url": "https://finnhub.io/api/news?id=c3772f53f83a434ed7f9aae160188d2d3b3af807c28fb0d612c383c545ed7636"
    },
    {
        "category": "company",
        "datetime": 1734517878,
        "headline": "Gilead Sciences, Inc. - U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer",
        "id": 132039374,
        "image": "",
        "related": "GILD",
        "source": "Finnhub",
        "summary": "FOSTER CITY - Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adult patients with...",
        "url": "https://finnhub.io/api/news?id=55a9274b0cb17c7a2322a47bd594a7483b09d5eb6d981abf8ea6f86a441b792b"
    },
    {
        "category": "company",
        "datetime": 1734509400,
        "headline": "My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys",
        "id": 132038523,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
        "related": "GILD",
        "source": "SeekingAlpha",
        "summary": "Financial writer achieves record dividend income in November through investments in BDCs, inching closer to $10,000 annual goal.",
        "url": "https://finnhub.io/api/news?id=1622bfcd6476b1f6935d84f1ad53065555594e875fe18e2d92fb59ae55233c0a"
    }
]